肝小静脉闭塞病新药去纤苷在国内上市了吗？

(also called defibrinated sodium) is a polydisperse mixture of single-stranded oligonucleotides that can prevent endothelial cell damage without increasing the risk of systemic bleeding, and protect liver sinusoidal endothelial cells without weakening the anti-tumor effect of cytotoxic drugs. Defibrinoside has antithrombotic, anti-ischemic, anti-inflammatory and profibrinolytic properties. Today we will learn in detail whether the new drug defibrinoside for hepatic veno-occlusive disease has been launched in China?

Defibrotide (also called defibrotide sodium) has not yet been officially launched in China. Patients in need can purchase the version available abroad. According to Medical Companion Travel, the price of defibrotide is about 22,000. Patients can purchase drugs abroad or obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), and sign a guarantee contract to guarantee 100% authenticity!

A multicenter phase II randomized study divided 150 HVOD patients into two groups, who were treated with defibrinoside 25 mg/kg (group A) and 40 mg/kg (group B) every day, with a median treatment time of 19 (1-82) days. Results: 141 patients were evaluable for efficacy: 65 patients achieved complete remission (46%), and 62 patients were still alive at 100 days (41%). Although grade 3/4 events in patients in group B included increased bleeding and hypotension, the difference was not statistically significant compared with patients in group A, indicating that the side effects of high-dose defibrotide were smaller and that defibrotide was safe and effective in the treatment of HVOD.

Defibrotide (also called defibrotide sodium) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects.

Defibrotide is the first drug approved by the U.S. FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic venous obstruction (VOD) who have undergone blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or lung function abnormalities. The drug has also received "orphan drug" designation.

On October 22, 2013, defibrotide (also called defibrotide sodium) was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defibrotide was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States on March 30, 2016.

The above is the content of the listing of (also called fiber-free sodium), I hope it can help you!